Relationship between CYP1A1 polymorphism, serum selenium and lung cancer

  Objective   To study the correlation of polymorphism of CYP1A1Msp1 and seurm selenium level independently and in combination with the risk of lung cancer.

  Methods   A case-control study was conducted, which included 58 cases of lung cancer and 62 controls. The genotypes of CYP1A1 were detected by PCR-RELP and the serum selenium level was determined by GHAFS.

  Results   There was no significant difference in polymorphism frequencies of CYP1A1 Msp I between the two groups. The genotypes were no significantly associated with the risk of lung cancer; Average serum level of selenium among the lung cancer cases was significantly lower than that among controls(P=0.001);Comparing with those who had higher serum selenium(> 0.109 mg/L)with CYP1A1m₁ m₁, the odds ratios of those who had lower serum selenium(< 0.109 mg/L)with CYP1A1m₂ m₂, with CYP1A1m₁m₂, with CYP1A1m₁ m₁ were 9.00(P=0.006), 3194(P=01195), 5.40(P=0.036)respectively, and those who had higher serum selenium with CYP1A1 m₂m₂, with CYP1A1m₁ m₂ were 1.69(P=0.500), 1.13(P=0.705)respectively.

  Conclusion   Polymorphism of CYP1A1 was not associated with the risk of lung cancer, but there was significant inverse association between the serum selenium level and the risk of lung cancer. A combined effect of polymorphism of CYP1A1 Msp I and serum selenium level on the risk of lung cancer was suggested.